35,562 reports of this reaction
7.3% of all ESOMEPRAZOLE MAGNESIUM reports
#1 most reported adverse reaction
CHRONIC KIDNEY DISEASE is the #1 most commonly reported adverse reaction for ESOMEPRAZOLE MAGNESIUM, manufactured by AstraZeneca Pharmaceuticals LP. There are 35,562 FDA adverse event reports linking ESOMEPRAZOLE MAGNESIUM to CHRONIC KIDNEY DISEASE. This represents approximately 7.3% of all 489,170 adverse event reports for this drug.
Patients taking ESOMEPRAZOLE MAGNESIUM who experience chronic kidney disease should discuss this symptom with their healthcare provider to determine whether it may be related to their medication and what alternatives may be available.
CHRONIC KIDNEY DISEASE is moderately reported among ESOMEPRAZOLE MAGNESIUM users, representing a notable but not dominant share of adverse events.
In addition to chronic kidney disease, the following adverse reactions have been reported for ESOMEPRAZOLE MAGNESIUM:
The following drugs have also been linked to chronic kidney disease in FDA adverse event reports:
CHRONIC KIDNEY DISEASE has been reported as an adverse event in 35,562 FDA reports for ESOMEPRAZOLE MAGNESIUM. This does not prove causation, but indicates an association observed in post-market surveillance data.
CHRONIC KIDNEY DISEASE accounts for approximately 7.3% of all adverse event reports for ESOMEPRAZOLE MAGNESIUM, making it one of the most commonly reported side effect.
If you experience chronic kidney disease while taking ESOMEPRAZOLE MAGNESIUM, contact your healthcare provider. They can evaluate whether the symptom is related to your medication and discuss potential adjustments to your treatment plan. Do not stop taking prescribed medication without consulting your doctor.